Mathematical Biosciences and Engineering (MBE)

Defining candidate drug characteristics for Long-QT (LQT3) syndrome
Pages: 861 - 873, Volume 8, Issue 3, July 2011

doi:10.3934/mbe.2011.8.861      Abstract        References        Full text (702.7K)                  Related Articles

Aslak Tveito - Center for Biomedical Computing, Simula Research Laboratory, P.O. Box 134, Lysaker 1325, Norway (email)
Glenn T. Lines - Center for Biomedical Computing, Simula Research Laboratory, P.O. Box 134, Lysaker 1325, Norway (email)
Pan Li - Cardiac Bioelectricity & Arrhythmia Center, Washington University, St. Louis, MO 63130-4899, United States (email)
Andrew McCulloch - Department of Bioengineering, University of California San Diego, United States (email)

1 C. Antzelevitch, Ionic, molecular, and cellular bases of qt-interval prolongation and torsade de pointes, Europace, 4 (2007), 4-15.
2 T. Brennan, M. Fink and B. Rodriguez, Multiscale modelling of drug-induced effects on cardiac electrophysiological activity, European Journal of Pharmaceutical Sciences, 36 (2009), 62-77.
3 A. Burashnikov and C. Antzelevitch, A unique mechanism contributing to initiation of atrial fibrillation, Pacing Clin Electrophysiol, 29 (2006), 290-5.
4 C. E. Clancy and Y. Rudy, Linking a genetic defect to its cellular phenotype in a cardiac arrhythmia, Nature, 400 (1999), 566.
5 C. E. Clancy, Z. I. Zhu and Y. Rudy, Pharmacogenetics and anti-arrhythmic drug therapy: A theoretical investigation, Am. J. Physiol. Heart Circ. Physiol., 292 (2007), H66-75.
6 L. Hondeghem and B. G. Katzung, Test of a model of antiarrhythmic drug action. Effects of quinidine and lidocaine on myocardial conduction, Circulation, 61 (1980), 1217-1224.
7 J. Keener and J. Sneyd, "Mathematical Physiology," Springer, 2009.
8 L. M. Livshitz and Y. Rudy, Regulation of Ca2+ and electrical alternans in cardiac myocytes: Role of CAMKII and repolarizing currents, Am. J. Physiol. Heart Circ. Physiol., 292 (2007), 2854-2866.
9 J. A. Nelder and R. Mead, A simplex method for function minimization, Computer Journal, 7 (1965), 308-313.
10 Denis Noble, Jeremy Levin and William Scott, Biological simulations in drug discovery, Drug Discovery Today, 4 (1999), 10-16.
11 Y. Rudy, Modelling the molecular basis of cardiac repolarization, Europace, 9 (2007), vi17-vi19.
12 A. Tveito and G. T. Lines, A note on a method for determining advantageous properties of an anti-arrhythmic drug based on a mathematical model of cardiac cells, Mathematical Biosciences, 217 (2009), 167-173.       
13 S. Vecchietti, E. Grandi, S. Severi, I. Rivolta, C. Napolitano, S. G. Priori and S. Cavalcanti, In silico assessment of Y1795C and Y1795H SCN5A mutations: Implication for inherited arrhythmogenic syndromes, Am. J. Physiol. Heart Circ. Physiol., 292 (2007), 56-65.
14 D. W. Wang, K. Yazawa, N. Makita, Jr. A. L. George and P. B. Bennett, Pharmacological targeting of long qt mutant sodium channels, Journal of Clinical Investigation, 99 (1997), 1714-1720.
15 Zheng I. Zhu and Colleen E. Clancy, Genetic mutations and arrhythmia: Simulation from DNA to electrocardiogram, Journal of Electrocardiology, ISCE 32nd Annual Conference, 40 (2007), S47-S50.

Go to top